NCI Seeks Record Increase in Funding

The $4.18 billion National Cancer Institute budget request submitted by the Bush administration to Congress in April for fiscal year 2002 amounts to an 11.7 percent boost of $439 million over the current year's appropriation. The package, however, falls $850 million short of the amount NCI sought in its own "bypass budget" proposal. NCI requested $5.03 billion, a whopping 34 percent boost of $1.27 billion. The bypass budget is so-called because, under the National Cancer Act of 1971, NCI's bud

Written byTed Agres
| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

NCI requested $5.03 billion, a whopping 34 percent boost of $1.27 billion. The bypass budget is so-called because, under the National Cancer Act of 1971, NCI's budget request is submitted directly to the president, bypassing approval by the National Institutes of Health and the Department of Health and Human Services (HHS) that is required of other NIH institutes and centers.

This bypass budget represents the cancer institute's "strategic planning," says John Hartinger, NCI's associate director for budget and financial management. The budget submitted to Congress by the president, he says, does not contain the same level of detail and is not organized in the same way as is the bypass budget. "Once we get a budget number back from Congress, then the director and the advisers will allocate it back to the bypass budget areas," Hartinger explains. "We will be able to 'cross-walk' it back" to specific program areas outlined ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies